Abeona Therapeutics
Yahoo Finance • last month
Top Growth Companies With Insider Ownership In June 2026
Over the last 7 days, the United States market has experienced a 3.3% decline, yet it remains up by 22% over the past year with earnings anticipated to grow by 17% annually in the coming years. In this context, growth companies with substa... Full story
Yahoo Finance • last month
High Insider Stakes In Leading Growth Companies May 2026
The United States market has shown robust performance, climbing 1.8% in the last 7 days and up 28% over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, growth companies with high insider owner... Full story
Yahoo Finance • 2 months ago
Spotlight On 3 Growth Companies With Strong Insider Stakes
The United States market has shown robust performance with a 1.2% climb in the last week and a remarkable 29% increase over the past year, alongside expectations for earnings to grow by 17% annually in the coming years. In this thriving en... Full story
Yahoo Finance • 2 months ago
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
CLEVELAND, May 26, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in June 2026: 2026 Jefferies Global Healthcare Con... Full story
Yahoo Finance • 2 months ago
Abeona Therapeutics® Reports First Quarter 2026 Results and Provides Pipeline Update
- Three patients treated with ZEVASKYN® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with game changing potential in the field of s... Full story
Yahoo Finance • 2 months ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, May 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Na... Full story
Yahoo Finance • 4 months ago
Abeona Therapeutics Q4 Earnings Call Highlights
Abeona Therapeutics logo Key Points Abeona’s autologous cell therapy ZEVASKYN (approved April 2025) began commercial treatments in December 2025 after a sterility-test delay, with early traction — two patients treated so far, multiple bi... Full story
Yahoo Finance • 4 months ago
Pre-Market Earnings Report for March 17, 2026 : ESLT, GDS, TME, ATAT, CAAP, ASO, TSAT, HUYA, ABEO, STIM, ICCM, PSQH
The following companies are expected to report earnings prior to market open on 03/17/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Elbit Systems Ltd. (ESLT)is reporting for the quarter ending Decembe... Full story
Yahoo Finance • 4 months ago
Earnings week ahead: FDX, BABA, XPEV, MU, GIS, DOCU, OKLO, ACN, and more
[Quarterly Report Financial Analysis and Business Performance Review with Office Tools] Mohamad Faizal Bin Ramli/iStock via Getty Images Wall Street has entered a quieter phase of the earnings calendar, but the macro environment is shouti... Full story
Yahoo Finance • 5 months ago
Netflix Is Casting a Light on a Rare Disease. Pearl Jam’s Frontman Is Raising Cash to Cure It.
An organization started by Pearl Jam frontman Eddie Vedder and his wife, Jill, is using venture philanthropy to finance a cure for a rare genetic skin disease. Continue Reading... Full story
Yahoo Finance • 7 months ago
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the... Full story
Yahoo Finance • 7 months ago
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therap... Full story
Yahoo Finance • 8 months ago
Fanconi Anemia Market Research Report 2025-2035: Competitive Growth Driven by Rocket Pharmaceuticals, Foresee, Merck, and Abeona as Gene Therapy and CRISPR-Based Innovations Expand
Company Logo **Fanconi Anemia Market Growth Driven by Genetic Research and Healthcare Investments**Fanconi Anemia (FA) is a rare genetic disorder impacting bone marrow's ability to produce blood cells, leading to pancytopenia and increase... Full story
Yahoo Finance • 8 months ago
Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
- First anticipated ZEVASKYN® patient treatment shifted to 4Q 2025 following implementation of optimized release assay - - Strong and growing patient demand and treatment site network, along with broad market access provide foundation for... Full story
Yahoo Finance • 8 months ago
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 financial results and c... Full story
Yahoo Finance • 8 months ago
Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
CLEVELAND, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and... Full story
Yahoo Finance • 9 months ago
Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
CLEVELAND, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that its ABO-503 gene therapy for... Full story
Yahoo Finance • 9 months ago
Abeona Therapeutics® and Children's Hospital Colorado Announce Newest Treatment Center for ZEVASKYN® Gene Therapy
CLEVELAND, Ohio and AURORA, Colo., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) and Children's Hospital Colorado today announced activation of Children's Colorado as the newest Qualified Treatment Center (QTC... Full story
Yahoo Finance • 10 months ago
Should You Invest in Abeona Therapeutics (ABEO)?
Riverwater Partners, an investment management company, released its “Micro Opportunities Strategy” Q2 2025 investor letter. A copy of the letter can be downloaded here. The strategy underperformed the benchmark in the second quarter due to... Full story
Yahoo Finance • 11 months ago
Abeona Therapeutics® Reports Second Quarter 2025 Financial Results and Corporate Updates
- Received FDA approval for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - -... Full story